This article reports continuing progress toward New Zealand’s new Patents Act 2006.
The New Zealand Patents Bill was released in late 2004. In the interests of both international uniformity and indigenous rights, the Patents Bill proposes several changes to existing New Zealand patent law. It integrates elements of the existing 1953 legislation with various aspects of the current Australian and United Kingdom Acts, and adds some uniquely "kiwi" provisions. Most changes reflect public opinion and will be embraced, whereas others may be more controversial.
A synopsis of some of the more significant proposed changes was provided in our February 2005 IP News article (
Prior to being introduced before NZ Parliament, stakeholders were given the opportunity to comment as to errors in, or unintended consequences of the Draft Bill. It should be emphasised that the Draft Bill was only released under the rationale of obtaining feedback on its drafting, as opposed to revisiting the policy decisions incorporated within it. Accordingly, public submissions on "drafting issues" were intended to highlight instances in which ambiguous wording may not properly give effect to the relevant policy decisions, or could have unintended consequences.
Many submissions nonetheless raised or revisited a number of policy issues, including:
the continuing exclusion from patentability of methods of medical treatment of human beings;
the proposed allowability of computer software and business method patents;
the continuing absence of an extension of patent term for pharmaceuticals (itself, the subject of a separate review), in relation to the proposed retention of "springboarding", and the imminent launch of the Trans-Tasman Therapeutic Products Agency;
the proposed abolition of pre-grant opposition;
the proposed changes to examination, including an assessment of inventive step, the definition of "prior art base" and a new Australian-style duty of disclosure that requires an Applicant to provide search results;
clarification of the employee/employer relationship and derivation of title; and
the statutory basis upon which an employee may seek compensation for a commercially successful invention.
The next stage in passage of the Draft Bill into NZ law is that the Parliamentary Counsel Office will consider any appropriate amendments. The Bill will then pass to a Parliamentary Select Committee, where the policy decisions may be revisited, if appropriate, prior to it being passed before Parliament. Our initial estimate that the new Act would be in operation by now appears to have been "optimistic", and it now seems that the Bill will pass into NZ law early next year. The complementary Patents Regulations should follow shortly thereafter.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
This article enunciates the recent, much awaited, and landmark judgment delivered on September 16, 2016 by Hon'ble Delhi High Court throwing light on the important provisions of the Copyright Act, 1962.
Department of Industrial Policy and Promotion recently issued an office memorandum pursuant to receiving representations from various stakeholders for guidance with respect to the applicability of the provisions of Section 31D of the Copyright Act, 1957.
An Invention Disclosure Form is the documentation of the invention. This is a means to document particulars of your invention and submitting it to the patent attorney who is filing your patent application.
The Patents Act 1970, along with the Patents Rules 1972, came into force on 20th April 1972, replacing the Indian Patents and Designs Act 1911. The Patents Act was largely based on the recommendations of the Ayyangar Committee Report headed by Justice N. Rajagopala Ayyangar. One of the recommendations was the allowance of only process patents with regard to inventions relating to drugs, medicines, food and chemicals.
Some comments from our readers… “The articles are extremely timely and highly applicable” “I often find critical information not available elsewhere” “As in-house counsel, Mondaq’s service is of great value”
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).